Key Details
Price
$13.00Annual EPS
-$2.92Annual ROE
-49.86%Beta
1.24Events Calendar
Next earnings date:
Feb 26, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 05, 2018Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accelerated Approval for the treatment of male patients with Danon disease. The Danon disease treatment market is expected to reach $2.82 billion by 2030.
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
Rocket Pharmaceuticals (RCKT) could experience an increase in value due to increasing confidence in its potential earnings, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. Rocket's pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others.
FAQ
- What is the primary business of Rocket Pharmaceuticals?
- What is the ticker symbol for Rocket Pharmaceuticals?
- Does Rocket Pharmaceuticals pay dividends?
- What sector is Rocket Pharmaceuticals in?
- What industry is Rocket Pharmaceuticals in?
- What country is Rocket Pharmaceuticals based in?
- When did Rocket Pharmaceuticals go public?
- Is Rocket Pharmaceuticals in the S&P 500?
- Is Rocket Pharmaceuticals in the NASDAQ 100?
- Is Rocket Pharmaceuticals in the Dow Jones?
- When was Rocket Pharmaceuticals's last earnings report?
- When does Rocket Pharmaceuticals report earnings?
- Should I buy Rocket Pharmaceuticals stock now?